Novartis Ag (NVS) Current Assets (2009 - 2026)
Novartis Ag (NVS) posted Current Assets of $27.4 billion for Q2 2026, down 10.21% sequentially from $30.5 billion in Q4 2025, and up 5.44% YoY from $25.9 billion in Q2 2025.
Novartis Ag (NVS) Current Assets (2009 - 2026) Analysis & Trends
Novartis Ag has reported Current Assets for 18 years, with the latest figure at $27.4 billion in Q2 2026.
- Quarterly Current Assets rose 5.44% year-over-year to $27.4 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $27.4 billion (up 5.44% YoY) and the FY2025 annual result came in at $30.5 billion, up 2.55% from the prior year.
- Current Assets slipped to $27.4 billion in Q2 2026 per NVS's latest filing, from $30.5 billion in the prior quarter.
- Over five years, Current Assets peaked at $38.1 billion in Q2 2022 and troughed at $25.7 billion in Q2 2024.
- A 5-year average of $30.9 billion and a median of $30.5 billion in 2025 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2024: Current Assets climbed 21.86% in 2022, then retreated 23.29% in 2024.
- Over 5 years, Current Assets stood at $36.9 billion in 2022, then retreated by 17.42% to $30.5 billion in 2023, then decreased by 2.55% to $29.7 billion in 2024, then climbed by 2.55% to $30.5 billion in 2025, then slipped by 10.21% to $27.4 billion in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $27.4 billion, $30.5 billion, and $25.9 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 59.77 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 33.67 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 36.68 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 27.35 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 27.97 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 34.96 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 13.95 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 41.36 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 23.56 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 36.64 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.35 Bn |
| Dec 31, 2025 | 30.46 Bn |
| Jun 30, 2025 | 25.94 Bn |
| Dec 31, 2024 | 29.70 Bn |
| Jun 30, 2024 | 25.69 Bn |
| Dec 31, 2023 | 30.48 Bn |
| Jun 30, 2023 | 33.49 Bn |
| Dec 31, 2022 | 36.91 Bn |
| Jun 30, 2022 | 38.14 Bn |
| Dec 31, 2021 | 45.72 Bn |
| Jun 30, 2021 | 31.30 Bn |
| Dec 31, 2020 | 29.67 Bn |
| Jun 30, 2020 | 27.70 Bn |
| Dec 31, 2019 | 29.50 Bn |
| Jun 30, 2019 | 32.30 Bn |
| Dec 31, 2018 | 35.56 Bn |
| Jun 30, 2018 | 29.60 Bn |
| Dec 31, 2017 | 28.21 Bn |
| Sep 30, 2017 | 3.30 Bn |
| Jun 30, 2017 | 26.70 Bn |